Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Parrish

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 6, 2026
Management of gastrointestinal symptoms during oral immunotherapy: Guidance from OUtMATCH InvestigatorsSayantani B Sindher, Mirna Chehade, Evan S Dellon, et al.
The Journal of Allergy and Clinical Immunology|May 30, 2025
Introduction of allergenic foods after treatment with omalizumabJennifer Dantzer, Yamini Virkud, Julie Wang, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergiesR Sharon Chinthrajah, Michael Kulis, Stacie M Jones, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2025
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEMatthew Greenhawt, Deborah Albright, Sara Anvari, et al.
The New England Journal of Medicine|May 10, 2023
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut AllergyMatthew Greenhawt, Sayantani B Sindher, Julie Wang, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
BMJ Open|November 17, 2022
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trialKara-Louise Royle, Amy Beth Coulson, Karthik Ramasamy, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 6, 2026
Management of gastrointestinal symptoms during oral immunotherapy: Guidance from OUtMATCH InvestigatorsSayantani B Sindher, Mirna Chehade, Evan S Dellon, et al.
The Journal of Allergy and Clinical Immunology|May 30, 2025
Introduction of allergenic foods after treatment with omalizumabJennifer Dantzer, Yamini Virkud, Julie Wang, et al.
The Journal of Allergy and Clinical Immunology|November 14, 2025
Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergiesR Sharon Chinthrajah, Michael Kulis, Stacie M Jones, et al.
The New England Journal of Medicine|February 26, 2024
Omalizumab for the Treatment of Multiple Food AllergiesRobert A Wood, Alkis Togias, Scott H Sicherer, et al.
Lancet (London, England)|June 14, 2026
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trialMeletios A Dimopoulos, Fredrik Schjesvold, Chengcheng Fu, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 16, 2025
Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: Open-Label Extension to EPITOPEMatthew Greenhawt, Deborah Albright, Sara Anvari, et al.
The New England Journal of Medicine|May 10, 2023
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut AllergyMatthew Greenhawt, Sayantani B Sindher, Julie Wang, et al.
Pageof 6